NASDAQ:SLNO Soleno Therapeutics (SLNO) Stock Price, News & Analysis $53.01 0.00 (0.00%) As of 05/19/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Soleno Therapeutics Stock (NASDAQ:SLNO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Soleno Therapeutics alerts:Sign Up Key Stats Today's Range$53.01▼$53.0150-Day Range$30.05▼$53.0152-Week Range$29.43▼$90.32VolumeN/AAverage Volume1.75 million shsMarket Capitalization$2.76 billionP/E Ratio29.95Dividend YieldN/APrice Target$76.67Consensus RatingHold Company Overview Soleno Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations. The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges. Soleno has completed multiple clinical trials of DCCR in adults and adolescents with PWS, evaluating its effects on hyperphagia, body composition and metabolic parameters. In addition to PWS, Soleno is advancing a proprietary formulation called SEZ982 for the treatment of phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare inherited condition that leads to multi-systemic impairment due to deficient protein glycosylation. Since its inception, Soleno has built a development pipeline rooted in rigorous translational research and active engagement with patient advocacy communities. The company works closely with academic collaborators and clinical centers of excellence across North America and Europe to design studies that address the full spectrum of disease manifestations. Soleno’s team combines expertise in drug formulation, clinical trial execution and regulatory strategy to expedite the path from laboratory discovery to potential market approval. Led by an experienced management team with deep backgrounds in biotech development and commercialization, Soleno continues to expand its scientific capabilities and prepare for potential regulatory submissions. The company maintains strategic partnerships and seeks to broaden its portfolio by identifying additional rare disease opportunities where small‐molecule therapies can deliver meaningful clinical outcomes. Through a patient-focused model, Soleno aims to bring new treatment options to communities with high unmet medical needs.AI Generated. May Contain Errors. Read More Soleno Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreSLNO MarketRank™: Soleno Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 250th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingSoleno Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on no strong buy ratings, 3 buy ratings, 8 hold ratings, and 2 sell ratings.Upside PotentialSoleno Therapeutics has a consensus price target of $76.67, representing about 44.6% upside from its current price of $53.01.Amount of Analyst CoverageSoleno Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Soleno Therapeutics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth46.05% Earnings GrowthEarnings for Soleno Therapeutics are expected to grow by 46.05% in the coming year, from $3.67 to $5.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is 29.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is 29.95, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.06.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 5.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Soleno Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.38% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 2.88, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 12.52%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Soleno Therapeutics this week, compared to 12 articles on an average week.Search InterestOnly 2 people have searched for SLNO on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat Follows1 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.40% of the stock of Soleno Therapeutics is held by insiders.Percentage Held by Institutions97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Soleno Therapeutics' insider trading history. Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLNO Stock News HeadlinesSoleno Therapeutics (NASDAQ:SLNO) Raised to Hold at Wall Street ZenMay 23 at 1:40 AM | americanbankingnews.comSLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens BermanMay 11, 2026 | prnewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.May 24 at 1:00 AM | Porter & Company (Ad)Soleno Merger With Neurocrine Puts Profitability And Valuation In FocusMay 10, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNOMay 5, 2026 | globenewswire.comSLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class ActionMay 5, 2026 | prnewswire.comDEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersMay 5, 2026 | globenewswire.comSLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law FirmMay 5, 2026 | prnewswire.comSee More Headlines SLNO Stock Analysis - Frequently Asked Questions How have SLNO shares performed this year? Soleno Therapeutics' stock was trading at $46.30 at the beginning of 2026. Since then, SLNO stock has increased by 14.5% and is now trading at $53.01. How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its quarterly earnings results on Wednesday, February, 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.16. The company earned $91.73 million during the quarter, compared to analysts' expectations of $88.55 million. Soleno Therapeutics had a trailing twelve-month return on equity of 22.85% and a net margin of 33.70%. Read the conference call transcript. When did Soleno Therapeutics' stock split? Shares of Soleno Therapeutics reverse split on Friday, August 26th 2022.The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Soleno Therapeutics' major shareholders? Soleno Therapeutics' top institutional investors include Janus Henderson Group PLC (13.62%), Readystate Asset Management LP (1.83%), Commodore Capital LP (1.25%) and Pictet Asset Management Holding SA (1.19%). Insiders that own company stock include Vivo Opportunity, Llc, Perceptive Advisors Llc, Bhatnagar Anish, James H Mackaness, Kristen Yen, Michael F Huang, Patricia C Hirano and Matthew Pauls. View institutional ownership trends. How do I buy shares of Soleno Therapeutics? Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), Disc Medicine (IRON), Arista Networks (ANET) and Adobe (ADBE). Company Calendar Last Earnings2/25/2026Today5/24/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 SLNO's financial health is in the Green zone, according to TradeSmith. SLNO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:SLNO CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees30Year Founded1999Price Target and Rating Average Price Target for Soleno Therapeutics$76.67 High Price Target$125.00 Low Price Target$53.00 Potential Upside/Downside+44.6%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$1.77 Trailing P/E Ratio29.95 Forward P/E Ratio14.44 P/E GrowthN/ANet Income$20.89 million Net Margins33.70% Pretax Margin34.94% Return on Equity22.85% Return on Assets18.25% Debt Debt-to-Equity Ratio0.10 Current Ratio5.62 Quick Ratio5.32 Sales & Book Value Annual Sales$285.01 million Price / Sales9.69 Cash Flow$0.43 per share Price / Cash Flow124.10 Book Value$9.51 per share Price / Book5.57Miscellaneous Outstanding Shares52,120,000Free Float48,784,000Market Cap$2.76 billion OptionableOptionable Beta-2.22 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:SLNO) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFor 67 years, chip-making meant slicing a single silicon wafer into hundreds of pieces. Three companies just a...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
